Pseudofolliculitis Barbae
7
0
1
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
14.3%
1 terminated out of 7 trials
80.0%
-6.5% vs benchmark
14%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Shaving Satisfaction in Males With Skin Irritation From Shaving
Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial
Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus
Magic Shave Powder Gold's Affects on the Occurrence of Pseudofolliculitis Barbae
Pre-Shave Gel and Brush in Pseudofolliculitis Barbae
Low Fluence 1064nm Laser Hair Reduction for Pseudofolliculitis Barbae in Skin Types IV, V, VI
Effect of 15% Eflornithine Hydrochloride Cream on African-American Males With Pseudofolliculitis Barbae